COVID-19 - COVID-19 Test Complexity
When the FDA authorizes a test for COVID-19 under an Emergency Use Authorization (EUA), is it waived or non-waived test complexity ?
Any examples are for illustrative purposes only.
Organizations should consult the intended use described in the Letter of Authorization for the test:
Organizations that use Joint Commission accreditation for deemed status purposes should monitor the CMS website as waivers are being approved frequently and may include state-specific waivers. Click here to access the CMS website for COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers.
Additional Resources
Coronavirus (COVID-19) Guidance and Resources
Organizations should consult the intended use described in the Letter of Authorization for the test:
- For tests approved for use in high- and moderate-complexity laboratories, and organizations need to follow the requirements for nonwaived testing.
- For tests that are intended to be used in patient care settings (including hospitals, physician offices, urgent care, outreach clinics, and temporary patient care settings), such tests can be performed in patient care settings that have a CLIA Certificate of Waiver or Certificate of Compliance. These terms generally do not apply to home specimen collection or at home testing unless otherwise specified.
Please note that this is very different from the FDA's normal test approval process and is only allowed during the EUA. Once the EUA has ended, a test must be classified by the FDA. If a test is not classified, it would be considered a laboratory developed test (LDT) and defaults to high complexity.
Organizations that use Joint Commission accreditation for deemed status purposes should monitor the CMS website as waivers are being approved frequently and may include state-specific waivers. Click here to access the CMS website for COVID-19 Emergency Declaration Blanket Waivers for Health Care Providers.
Additional Resources
Coronavirus (COVID-19) Guidance and Resources
Manual:
Laboratory
Chapter:
Leadership LD
Last reviewed by Standards Interpretation: December 22, 2021
Represents the most recent date that the FAQ was reviewed (e.g. annual review).
First published date: April 10, 2020
This Standards FAQ was first published on this date.
This page was last updated on May 12, 2023
with update notes of: Review only, FAQ is current
Types of changes and an explanation of change type:
Editorial changes only: Format changes only. No changes to content. |
Review only, FAQ is current: Periodic review completed, no changes to content. |
Reflects new or updated requirements: Changes represent new or revised requirements.
Get Extra Help with Books and E-books
Browse our gallery of books and e-books to find trusted prep and readiness resources, practical checklists and toolkits, and resources on specialized health care topics.
Stay Informed with Online Education
Online education is the most convenient and cost-effective way to educate your staff and minimize expenses without the need to leave your organization.
Reach Your Safety Goals with eProducts
Assessing and sustaining compliance with accreditation standards or CMS CoPs can be a challenge, but it doesn’t have to be. Rely on our proven software solutions developed by our team of industry experts.
Joint Commission Virtual Assistant